LYTIR

Company · CAMP

CAMP4 Therapeutics Corporation

Name as listed on its exchange; filed with the SEC as Camp4 Therapeutics Corp.

Nasdaq's symbol directory lists CAMP on Nasdaq as “CAMP4 Therapeutics Corporation - Common Stock”.

In the 12 months to Nov 19, 2026: insiders bought on 5 occasions ($99K); insiders sold on 6 occasions ($2.5M); 9 filings by holders of 5% or more; 2 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Andrew J. Schwab sold on 5 days latest Aug 27, 2026 sold $2.5M
  2. Kelly Gold, Chief Financial Officer bought on 2 days latest Aug 31, 2026 bought $50K
  3. Young Richard A bought on 1 day latest Aug 3, 2026 bought $27K
  4. Mandel-Brehm Josh, Chief Executive Officer bought on 1 day latest Aug 3, 2026 bought $11K
  5. Maricich Yuri, Chief Medical Officer bought on 1 day latest Aug 3, 2026 bought $11K
  6. Tardiff Daniel, Chief Scientific Officer sold on 1 day latest Aug 19, 2026 sold $8K
Every trade (11)
  1. BUYKelly Gold, Chief Financial Officer bought Aug 31, 2026 10,000 shares filing $40K
  2. SELLAndrew J. Schwab sold Aug 27, 2026 400,000 shares filing $1.6M
  3. SELLAndrew J. Schwab sold Aug 24, 2026 10 shares filing $45
  4. SELLAndrew J. Schwab sold Aug 21, 2026 32,018 shares filing $144K
  5. SELLAndrew J. Schwab sold Aug 20, 2026 114,700 shares filing $521K
  6. SELLAndrew J. Schwab sold Aug 19, 2026 45,147 shares filing $215K
  7. SELLTardiff Daniel, Chief Scientific Officer sold Aug 19, 2026 1,738 shares filing $8K
  8. BUYYoung Richard A bought Aug 3, 2026 16,378 shares filing $27K
  9. BUYKelly Gold, Chief Financial Officer bought Aug 3, 2026 6,551 shares filing $11K
  10. BUYMandel-Brehm Josh, Chief Executive Officer bought Aug 3, 2026 6,551 shares filing $11K
  11. BUYMaricich Yuri, Chief Medical Officer bought Aug 3, 2026 6,551 shares filing $11K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Vivo Opportunity Fund Holdings, L.P. filed Nov 16, 2026 Schedule 13G/A passive filing 9.99%
  2. Coastlands Capital LP filed Nov 13, 2026 Schedule 13G/A passive filing 9.99%
  3. Adage Capital Management, L.P. filed Nov 12, 2026 Schedule 13G passive filing 6.68%
  4. FMR LLC filed Nov 5, 2026 Schedule 13G/A passive 4,908,857 shares filing 7.8%
  5. 5AM Ventures VI, L.P. filed Aug 31, 2026 Schedule 13D/A may seek influence 6,379,125 shares filing 9.9%
  6. Polaris Management Co. VII, L.L.C. filed Aug 19, 2026 Schedule 13D/A may seek influence 3,023,161 shares filing 4.8%
  7. BALYASNY ASSET MANAGEMENT L.P. filed Aug 14, 2026 Schedule 13G/A passive filing 4.99%
  8. Trails Edge Capital Partners, LP filed Aug 10, 2026 Schedule 13G passive filing 6%
  9. 5AM Ventures VI, L.P. filed Aug 5, 2026 Schedule 13D/A may seek influence 2,625,145 shares filing 4.2%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Financial statements and exhibits filing Nov 5, 2026
  2. Regulation FD disclosure; Other events filing Sep 28, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.